Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 3;12:851795. doi: 10.3389/fonc.2022.851795

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liu, Shen, Wang, Wu, Chang, Chen, Lee and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Combined treatment by RU.521 and EGFR inhibitors suppressed the growth of tumor organoids derived from breast cancer patients. Tumor organoids derived from breast cancer patients (#1 and #2) were cultured and treated with RU.521 alone (20 μM), EGFR inhibitors (afatinib (A) or gefitinib (C)) alone (10 μM), or co-treated with RU.521 plus an EGFR inhibitors (afatinib (A) or gefitinib (C)) in serum-replete media for 72 hr. (A, C) Representative images of organoids captured by an inverted microscope at 100x magnification are shown. Bar, 100 μm. (B, D) the volumes of the derived organoids (n=5 of #1, n=3 of #2 for each treatment) after the indicated treatments were estimated by the sphere volume formula (V=4/3πr3). The data of three independent experiments were shown as means ± SD, and statistical significance was plotted by Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.